Switch theme
Sign up to access all valuation multiples
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, Mexico, Chile, and others. The company's key revenue is derived from Canada.
1996
15
LTM Revenue n/a
LTM EBITDA n/a
$17.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diagnos has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Diagnos achieved revenue of $0.1M and an EBITDA of -$1.7M.
Diagnos expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diagnos valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.3M | $0.1M | XXX | XXX | XXX |
| Gross Profit | -$0.3M | -$0.2M | XXX | XXX | XXX |
| Gross Margin | -86% | -180% | XXX | XXX | XXX |
| EBITDA | -$1.5M | -$1.7M | XXX | XXX | XXX |
| EBITDA Margin | -432% | -1438% | XXX | XXX | XXX |
| Net Profit | -$1.8M | -$1.7M | XXX | XXX | XXX |
| Net Margin | -537% | -1458% | XXX | XXX | XXX |
| Net Debt | $0.4M | $1.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Diagnos's stock price is CAD 0 (or $0).
Diagnos has current market cap of CAD 24.7M (or $17.3M), and EV of CAD 25.2M (or $17.6M).
See Diagnos trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.6M | $17.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Diagnos has market cap of $17.3M and EV of $17.6M.
Diagnos's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Diagnos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Diagnos and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $17.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDiagnos's NTM/LTM revenue growth is n/a
Diagnos's revenue per employee for the last fiscal year averaged $8K, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Diagnos's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Diagnos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Diagnos and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -65% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $8K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1030% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diagnos acquired XXX companies to date.
Last acquisition by Diagnos was XXXXXXXX, XXXXX XXXXX XXXXXX . Diagnos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Diagnos founded? | Diagnos was founded in 1996. |
| Where is Diagnos headquartered? | Diagnos is headquartered in Canada. |
| How many employees does Diagnos have? | As of today, Diagnos has 15 employees. |
| Is Diagnos publicy listed? | Yes, Diagnos is a public company listed on TSX. |
| What is the stock symbol of Diagnos? | Diagnos trades under ADK ticker. |
| When did Diagnos go public? | Diagnos went public in 2000. |
| Who are competitors of Diagnos? | Similar companies to Diagnos include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Diagnos? | Diagnos's current market cap is $17.3M |
| What is the current revenue growth of Diagnos? | Diagnos revenue growth between 2023 and 2024 was -65%. |
| Is Diagnos profitable? | Yes, Diagnos is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
